Coronavirus | Roche India gets emergency use approval for antibody cocktail used in COVID-19 treatment
The Hindu
The approval of antibody cocktail of Casirivimab and Imdevimab in India was based on the data filed for the emergency use authorisation in the U.S., Roche India said in a statement
on Wednesday said it has received emergency use authorisation from the Central Drugs Standards Control Organisation (CDSCO) for Roche's investigational antibody cocktail used in the treatment of COVID-19. The approval of antibody cocktail of Casirivimab and Imdevimab in India was based on the data filed for the emergency use authorisation in the U.S., and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union, Roche India said in a statement. "This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla Limited," it added.More Related News